Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female participants between 18 years and 75 years old, with relapsed or refractory HL or relapsed or refractory sALCL who have previously received at least 1 multiagent chemotherapy
Measurable disease
An Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1
Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence
Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence
Clinical laboratory values as specified in the study protocol
You may not be if
Participants for whom rifampicin is contraindicated
Previously received an allogeneic transplant.
Participants with current diagnosis of primary cutaneous anaplastic large cell lymphoma (ALCL) (participants whose ALCL has transformed to sALCL are eligible).
Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
Female participants who are lactating and breastfeeding or pregnant
Known human immunodeficiency virus (HIV) positive,
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Clareo Health | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
